Anesthesia for Cardioversion and Electrophysiologic Procedures





Key Points




  • 1.

    Tachyarrhythmias result from one of three mechanisms (reentry, automaticity, and triggered activity), with reentry being the mechanism most commonly treated in the electrophysiology (EP) laboratory.


  • 2.

    Anesthetic agents influence cardiac conduction and arrhythmogenesis and can adversely affect EP procedures.


  • 3.

    Opioids may have an antiarrhythmic effect in the setting of myocardial ischemia.


  • 4.

    While the arrhythmic properties of volatile anesthetics are controversial, overall they have an antifibrillatory effect.


  • 5.

    Two new, more minimally invasive cardiac implantable electrical devices include the subcutaneous implantable cardioverter-defibrillator and leadless pacemaker.


  • 6.

    General anesthesia is becoming increasingly preferred for atrial fibrillation ablation because of the longer procedure time and predictable thoracic excursion with mechanical ventilation.


  • 7.

    Atrial fibrillation is responsible for more than 35% of ischemic strokes, with the left atrial appendage being the most common place for thrombus formation.


  • 8.

    Complications of procedures performed in the EP laboratory are secondary to vascular access, thromboembolism, arrhythmias, pericardial effusions, air embolism, pulmonary vein stenosis, atrioesophageal fistula formation, and phrenic nerve injury.



Cardiac arrhythmias cause significant morbidity and mortality. In the United States, cardiac arrhythmias account for nearly 400,000 deaths annually. Since the implantation of the first cardiac pacemaker in 1958, clinical electrophysiology (EP) has become increasingly complex and now includes a variety of sophisticated therapeutic and diagnostic procedures. Although sedation for many EP cases has historically been performed by a nurse under the direction of the proceduralist, because of a number of factors (complexity of many of these cases, long procedural times, potential significant hemodynamic instability, and significant patient comorbidities often present), an anesthesia provider is now frequently integral to providing safe and effective EP care. Understanding the basic principles of how these procedures are performed, the mechanisms of cardiac arrhythmias, and the impact that anesthetic agents have on the cardiac conduction system is paramount for anesthesia providers working in this environment.


This chapter provides an overview of clinical EP for anesthesia providers. It discusses the effects of the most commonly used anesthetic agents in the EP laboratory on cardiac conduction. It reviews the salient details and anesthetic considerations of each of the main EP procedures as well as the associated complications that might arise during the periprocedural period. See Table 15.1 for commonly used abbreviations in clinical EP.



Table 15.1

Commonly Used Abbreviations in Clinical Electrophysiology











































































AF Atrial fibrillation
AFL Atrial flutter
AT Atrial tachycardia
AVNRT Atrioventricular nodal reentrant tachycardia
AVRT Atrioventricular reciprocating tachycardia
CARTO Navigation system produced by Biosense Webster
CIED Cardiovascular implantable electronic device
CS Coronary sinus
EC Electrical cardioversion
EP Electrophysiology
EGM Electrogram (generally intracardiac)
hRA High right atrium
ICD Implantable cardioverter-defibrillator
ICE Intracardiac echocardiogram
LAA Left atrial appendage
NavX Navigation system (St. Jude Medical)
PDNA Proceduralist-directed nurse-administered
PSVT Paroxysmal supraventricular tachycardia
PVC Premature ventricular contraction
PVI Pulmonary vein isolation
SVT Supraventricular tachycardia
TdP Torsades de pointes
VF Ventricular fibrillation
VT Ventricular tachycardia




Overview of Electrophysiology Procedures


Electrophysiology Laboratory


Initially, the main purpose of the EP laboratory was for diagnostic studies. However, its focus has evolved to include many therapeutic procedures such as catheter ablation and cardiac rhythm device implantation and extraction. The EP laboratory is divided into the control room, which is shielded from radiation by a glass partition and doorway, and the area where the procedure is performed, which contains the patient table and imaging equipment. While the procedure is being performed, a technician (and sometimes a second electrophysiologist) in the control room monitors the patient’s cardiac rhythm and performs various pacing maneuvers. A large amount of equipment is required (e.g., single or biplane fluoroscopy, mapping patches, electrocardiogram [ECG] leads, catheters, boom with multiple screens), limiting access to the patient during the procedure and thus complicating anesthetic care. Some laboratories also contain a magnetic catheter navigation system (e.g., Stereotaxis Inc.), which occupies even more space and introduces the logistical considerations (i.e., magnetic resonance imaging [MRI]-compatible monitors and anesthesia machine) and potential dangers of a ferromagnetic field. Because fluoroscopy is constantly used in the EP laboratory, necessary radiation safety precautions (e.g., lead aprons or shields, eye protection) must be followed. Radiation dosimeters should be worn by personnel who routinely work in this environment.


Catheter Placement and Generation of Intracardiac Electrograms


Right heart catheter placement is most often performed via the femoral vein; however, the internal jugular, subclavian, or brachial vein can be used. Multiple intravenous (IV) sheaths are placed so that catheters can be advanced into the heart to record intracardiac signals (electrograms). In contradistinction to the surface ECG, which provides summed vectors of the heart’s electrical activity, the intracardiac electrogram records a discrete local signal from a small area of the myocardium. These diagnostic catheters, some with multiple electrode pairs, are used to determine information such as signal voltage, complexity, and local activation (timing compared with a reference). The exact type and location of the catheters placed depend on the procedure being performed and physician preference.


To perform a basic EP study, several electrograms are typically obtained by placing catheters into the high right atrium (hRA), coronary sinus (CS), His bundle, and RV apex (RVa) ( Fig. 15.1 ). A variable number of surface ECGs leads are also displayed. To better visualize the signals, they are displayed at a sweep speed of 100 mm/s compared with 25 mm/s for a standard ECG. Real-time signals are viewed on one screen, and an additional screen is available for measurements and static review.




Fig. 15.1


Intracardiac electrograms obtained during a standard electrophysiology study in a patient with ventricular preexcitation. This screen shot shows the intracardiac and surface electrocardiogram (ECG) recordings obtained while a high right atrial catheter was used to pace the atrium. Displayed are three surface ECG leads (I, aVF, V1), and the following intracardiac recordings: high right atrial (HRA), three His (proximal, mid, distal), five coronary sinus (CS), and a right ventricular apex (RVa). The bottom-most tracing is a stimulation channel (Stim 1), which confirms pacing is being performed. The pacing artifact seen on the surface ECG may not necessarily be seen on the anesthesia team’s monitor, and review of the stimulation channel on the screen can confirm that pacing is occurring. In this patient, the short PR interval and delta wave visible on the surface ECG leads are characteristic of ventricular preexcitation.


Catheter Mapping System


Mapping systems are used to collect and display information gathered from intracardiac recordings. A three-dimensional (3D) shell of the chamber(s) of interest is generated along with pertinent timing and voltage information. These systems reduce radiation exposure compared with fluoroscopy alone by integrating preprocedural images obtained from computed tomography (CT) or magnetic resonance (MR) or use intraprocedural ultrasound to improve anatomic relationships. During an arrhythmia, an activation map is produced by measuring the timing of different cardiac events and then using color coding or an animation to display the wavefront proceeding across the 3D map ( Fig. 15.2 ). The map helps the electrophysiologist determine the area that should be targeted for ablation by pinpointing the source of a focal tachycardia or the area of slow conduction in the case of a macroreentrant tachycardia. Voltage mapping is used in addition to or in lieu of activation mapping if an arrhythmia is noninducible and provides important information about the scar substrate responsible for reentrant rhythms.




Fig. 15.2


An activation map showing typical atrial flutter with counterclockwise rotation (arrows) . The color bar (located on the left edge of the image) provides a reference for timing and color correlation. Earliest activation sites are noted by white followed by red, with purple indicating the last activated site compared to the reference time. A macroreentrant circuit is continuous; thus early and late are arbitrarily defined, but the so-called “early meets late” pattern supports the mechanism as reentry rather than a focal tachycardia. The right atrium is seen in both the right anterior oblique view (image on left) and left anterior oblique caudal view (image on right). CS, Coronary sinus; HB, His bundle; IVC, inferior vena cava; RAA, right atrial appendage; SVC, superior vena cava.


Mechanisms of Cardiac Arrhythmias


Arrhythmias are classified as slow (bradyarrhythmia) or fast (tachyarrhythmia) based on whether the heart rate is less than 60 beats/min or greater than 100 beats/min, respectively.


Bradyarrhythmias


A bradyarrhythmia results from failure of impulse formation or conduction. The most commonly treated bradyarrhythmia in the EP laboratory is sinus node (SN) dysfunction, which occurs when impulse formation is impaired within the SN. Conduction system disease is most often from advanced age or underlying cardiovascular disease and results in three main forms of atrioventricular (AV) block—first, second, or third degree.


First-degree AV block is actually a misnomer because in this condition conduction through the AV node is simply slowed, which results in a prolonged PR interval on the ECG and requires no treatment. Second-degree AV block is subdivided into types I and II; these conditions partially impair but do not entirely block impulses from conducting to the ventricles. On the ECG, type I is diagnosed by progressive PR prolongation until a dropped ventricular beat occurs. In contrast, type II is characterized by intermittent nonconducted P-waves without progressive PR prolongation. Type II is important to identify because it indicates infranodal conduction disease, can progress to third-degree heart block, and might warrant pacemaker implantation. In third-degree heart block, there is complete AV dissociation, which requires a junctional or ventricular escape rhythm to maintain perfusion.


Tachyarrhythmias


Tachyarrhythmias are caused by one of three mechanisms ( Box 15.1 ). In the EP laboratory, the most commonly treated mechanism is reentry. A reentrant tachycardia is defined by its continuous circular path in which the wavefront of excitability returns to the site of initiation. Requirements of reentry include two adjacent pathways with differing EP properties that connect proximally and distally to form a single circuit with a nonexcitable central area. Unidirectional block is required and occurs when differences in refractory periods allow an impulse to initially conduct down one pathway but not the other. Because of slow conduction, by the time the wavefront reaches the end of the first pathway, the second pathway is no longer refractory and accepts the impulse. The impulse then continues until it returns to its origin and thus completes one cycle of tachycardia. There is often an area of slow conduction that facilitates reentry and may be targeted for ablation (e.g., the cavotricuspid isthmus in typical atrial flutter [AFL]).



Box 15.1

Tachyarrhythmia Mechanisms





  • Reentry (mechanism most commonly addressed in electrophysiology procedures)



  • Automaticity



  • Triggered




The remaining two mechanisms, automaticity and triggered activity, are abnormalities in impulse formation rather than conduction. Automaticity is spontaneous impulse formation and is normal behavior when occurring in specialized conduction tissue. Failure of automaticity may result in a bradyarrhythmia such as sinus bradycardia. Alternatively, increased automaticity in diseased or ischemic atrial or ventricular myocardial cells may result in a sustained tachyarrhythmia or induce premature beats that initiate reentry. Triggered activity requires a preceding impulse and is caused by oscillations in the cellular membrane potential called afterdepolarizations. Afterdepolarizations are further characterized as early or delayed depending on when they occur during the action potential. Clinical examples of early and delayed afterdepolarizations include torsades de pointes in long-QT syndrome and digoxin toxicity, respectively. Table 15.2 summarizes key characteristics of the different tachyarrhythmias treated in the EP laboratory.



Table 15.2

Tachyarrhythmias Treated in the Electrophysiology Laboratory

















































Arrhythmia Mechanism Ablation Target Sedation Level Needed
AV nodal reentry Reentry Slow pathway Moderate
AV reciprocating tachycardia Reentry Accessory pathway Moderate
Atrial tachycardia Reentry, triggered activity, automaticity Origin of focal tachycardia Moderate
Atrial flutter Reentry Area of slow conduction Moderate
Atrial fibrillation Multiple mechanisms coexist Pulmonary vein isolation initially Moderate to general anesthesia
PVCs Automaticity, reentry, triggered activity PVC focus (outflow tract most common) Moderate
VT with a structurally normal heart Automaticity, reentry, triggered activity VT focus Moderate
VT with structural heart disease Reentry caused by fibrosis Critical isthmus or extensive substrate modification General anesthesia

AV, Atrioventricular; PVC, premature ventricular contraction; VT, ventricular tachycardia.




Anesthetic Agents and Cardiac Conduction


Many anesthetic agents influence cardiac conduction and arrhythmogenesis and thus have the propensity to adversely impact the efficacy of the diagnostic and therapeutic procedures performed in the EP laboratory. The most commonly used sedative and anesthetic agents along with a description of their varying effects on the cardiac conduction system are provided next. A summary of this information is also contained in Table 15.3 .



Table 15.3

Summary of Anesthetic Agent Effects on Cardiac Conduction and Electrical Properties







































































































Agent Antiarrhythmic Properties Proarrhythmic Properties Acceptable for Use in Cardioversion Effect on P-R Interval Effect on QTc Interval Benefits Adverse Effects
Propofol May terminate SVT
May convert AF
May terminate VT
Bradycardia
Lengthens SA node interval
Slows AVN conduction/prolongs AVN effective refractory period
Slows atrial rate
Case reports of TdP
Yes May shorten Varying reports:
Primarily prolongs
May shorten
Rapid onset and recovery Vasodilation
Dose-dependent decrease in blood pressure
Possible P-wave dispersion
Etomidate None None Yes NR NR Minimal cardiac depressive effects Adrenocortical suppression
Midazolam NR NR Yes NR None Amnesia
Minimal HD effects
Mild venous dilation but no significant impact on contractility
Dexmedetomidine Bradycardic effect has been used in SVT, VT, AFL, junctional ectopic tachycardia SA node interval lengthening in some reports
Slows AVN conduction or blockade
Yes Prolongs Prolongs Rapid onset/clearance Use with caution in heart block, bradycardia, and heart transplant
Caution when coadministered with β-blockade
Sevoflurane Antifibrillatory Atrial ectopy in pediatric reports
Slowing of AVN conduction time
Yes NR Prolongs Not noxious to airways Dose-dependent vasodilation
Desflurane Antifibrillatory Slowing of AVN conduction time Yes NR Prolongs Lowest blood:gas solubility of the three listed volatile agents Dose-dependent vasodilation
Isoflurane Antifibrillatory Slowing of AVN conduction time
APERP prolongation in preexcitation syndromes
Yes NR Prolongs Inexpensive Dose-dependent vasodilation
Fentanyl Antifibrillatory; elongates the sinus node recovery time Bradycardia Yes NR None Inexpensive No amnestic effect
Ventilation depressant
May affect accuracy of atrial mapping during EP procedures
Morphine Decreases the occurrence of reperfusion-induced arrhythmias
Antifibrillatory
Bradycardia Yes NR None Inexpensive Vasodilation secondary to histamine release
Remifentanil NR Bradycardia
Slows SA node function
Slows AVN conduction and prolongs AVN ERP
Yes NR None; may attenuate QTc prolongation in hypertensive patients Ultrarapid onset and recovery No amnesia
Ventilation depressant
Hypotension
Bradycardia
Caution with β-blockade

AF, Atrial fibrillation; AFL, atrial flutter; APERP, accessory pathway effective refractory period in pre-excitation syndromes; AVN, atrioventricular node; EP, electrophysiology; ERP, effective refractory period; HD, hemodynamic; NR, none reported; SA, sinoatrial; SVT, supraventricular tachycardia; TdP, torsades de pointes; VT, ventricular tachycardia.

Only gold members can continue reading. Log In or Register to continue

Stay updated, free articles. Join our Telegram channel

Dec 26, 2019 | Posted by in CARDIOLOGY | Comments Off on Anesthesia for Cardioversion and Electrophysiologic Procedures

Full access? Get Clinical Tree

Get Clinical Tree app for offline access